Agrobacterium tumefaciens ExoR represses succinoglycan biosynthesis and is required for biofilm formation and motility

por Tomlinson, Amelia D., Ramey-Hartung, Bronwyn, Day, Travis W., Merritt, Peter M., Fuqua, Clay
Publicado 2010

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis

por Henn, Matthew R., O’Brien, Edward J., Diao, Liyang, Feagan, Brian G., Sandborn, William J., Huttenhower, Curtis, Wortman, Jennifer R., McGovern, Barbara H., Wang-Weigand, Sherry, Lichter, David I., Chafee, Meghan, Ford, Christopher B., Bernardo, Patricia, Zhao, Peng, Simmons, Sheri, Tomlinson, Amelia D., Cook, David N., Pomerantz, Roger J., Misra, Bharat K., Auninš, John G., Trucksis, Michele
Publicado 2021

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

por McGovern, Barbara H, Ford, Christopher B, Henn, Matthew R, Pardi, Darrell S, Khanna, Sahil, Hohmann, Elizabeth L, O’Brien, Edward J, Desjardins, Christopher A, Bernardo, Patricia, Wortman, Jennifer R, Lombardo, Mary-Jane, Litcofsky, Kevin D, Winkler, Jonathan A, McChalicher, Christopher W J, Li, Sunny S, Tomlinson, Amelia D, Nandakumar, Madhumitha, Cook, David N, Pomerantz, Roger J, Auninš, John G, Trucksis, Michele
Publicado 2020